PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Cost reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
12.50%
Gross profit growth exceeding 1.5x TRAW's 1.92%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth less than half of TRAW's 107.55%. David Dodd would verify if efficiency advantage is sustainable.
21.30%
G&A growth while TRAW reduces overhead. John Neff would investigate operational differences.
100.00%
Marketing expense change of 100.00% while TRAW maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth above 1.5x TRAW's 12.78%. Michael Burry would check for inefficiency.
29.39%
Total costs growth above 1.5x TRAW's 12.78%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-30.36%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while TRAW shows 100.00% growth. Joel Greenblatt would examine advantage.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.58%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.95%
Share count reduction exceeding 1.5x TRAW's 20.28%. David Dodd would verify capital allocation.
7.95%
Diluted share reduction exceeding 1.5x TRAW's 20.28%. David Dodd would verify capital allocation.